September 2016
Volume 57, Issue 12
Open Access
ARVO Annual Meeting Abstract  |   September 2016
Variation in Ophthalmologist Use of Anti-VEGF Therapy Among Medicare Beneficiaries
Author Affiliations & Notes
  • Rachel Thakore
    Warren Alpert Medical School of Brown University, Providence, Rhode Island, United States
  • Paul B Greenberg
    Ophthalmology, Warren Alpert Medical School of Brown University, Providence, Rhode Island, United States
    Ophthalmology, Providence VA Medical Center, Providence, Rhode Island, United States
  • Dustin French
    Department of Ophthalmology and the Center for Healthcare Studies, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, United States
    Veterans Affairs Health Services Research and Development Service, Chicago, Illinois, United States
  • Jess J Behrens
    Center for Healthcare Studies, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, United States
  • Footnotes
    Commercial Relationships   Rachel Thakore, None; Paul Greenberg, None; Dustin French, None; Jess Behrens, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science September 2016, Vol.57, 3344. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Rachel Thakore, Paul B Greenberg, Dustin French, Jess J Behrens; Variation in Ophthalmologist Use of Anti-VEGF Therapy Among Medicare Beneficiaries. Invest. Ophthalmol. Vis. Sci. 2016;57(12):3344.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : The type of anti-vascular endothelial growth factor (anti-VEGF) therapies used by ophthalmologists can vary considerably, impacting the costs of care. Using the recently released Medicare physician utilization data, we analyzed geographic trends in the use of anti-VEGF therapy amongst ophthalmologists across a two-year period (2012-2013).

Methods : Using Healthcare Common Procedure Coding System codes, we identified ophthalmologists who billed for ranibizumab (J2778), bevacizumab (J9035), and aflibercept (J0178/Q2046) in the 2012 and 2013 Medicare Provider Utilization and Payment Data: Physician and Other Supplier Public Use Files. We classified ophthalmologists to hospital referral regions (HRRs), urban/rural status, and Census regions using zip codes. We used ArcGIS (Redlands, CA, USA) to map the percentage of physicians in each HRR that used each anti-VEGF drug. We conducted chi-squared tests to determine 1) variation based on year, Census region, urban/rural status, and 2) geographic changes between 2012 and 2013.

Results : The Figure shows geographic variation based on HRRs. Aflibercept was used by the least number of physicians in 2012 (57.0%; n=1359) but was the most widely used medication in 2013 (69.6%; n=1835). In the west, bevacizumab was used by more ophthalmologists (91.5%; n=606) than aflibercept (57.3%; n=379) and ranibizumab (52.4%; n=347). In the Midwest, more ophthalmologists used aflibercept (81.2%; n=423) and ranibizumab (77.0%; n=401) than bevacizumab (19.4%; n=101). There was significant variation in anti-VEGF drug use based on the year (p<0.0001), Census region (p<0.0001), and urban/rural status of the ophthalmologist (p<0.0001) [Table]. From 2012 to 2013, the number of ophthalmologists using bevacizumab increased from 9.9% (43/434) to 19.0% (95/500) in the Midwest and 84.3% (493/585) to 90.2% (573/635) in the west (p<0.001).

Conclusions : From 2012 to 2013, there was significant geographic variation in anti-VEGF drug use among ophthalmologists as well as significant changes in prescribing patterns. Further research is needed to identify the major determinants of this geographic variation and how these trends may impact future Medicare costs.

This is an abstract that was submitted for the 2016 ARVO Annual Meeting, held in Seattle, Wash., May 1-5, 2016.

 

Anti-Vascular Endothelial Growth Factor Drug(s) Used by the Greatest Percentage of Ophthalmologists per Hospital Referral Regions, 2012/2013.

Anti-Vascular Endothelial Growth Factor Drug(s) Used by the Greatest Percentage of Ophthalmologists per Hospital Referral Regions, 2012/2013.

 

Variation in Anti-VEGF drugs by year, urban/rural status, and Census region

Variation in Anti-VEGF drugs by year, urban/rural status, and Census region

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×